Latest Anemia News
Investigators find that the normalized mean ESA dose decreases as patients' elevation of residence increases.
Researchers confirmed higher dose conversion ratios in Taiwanese patients with stable hemoglobin.
New findings implicate transferrin saturation and nutritional status assessed by albumin.
After 54 weeks of treatment with testosterone undecanoate, anemia prevalence decreased from 29.6% to 10%.
Trend is independent of intravenous iron use and exposure to erythropoiesis-stimulating agents.
No new adverse events observed in patients with underlying cardiovascular risk factors who switched to continuous erythropoietin receptor activator.
Greater hyporesponsiveness to erythropoiesis-stimulating agents was associated with increased PLR ratios.
Observed rates of all-cause and cardiovascular mortality and myocardial infarction were consistent with expected rates, study shows.
Researchers observe significantly higher levels of albumin and hemoglobin and better calcium and phosphate metabolism.
Based on effect of erythropoietin-stimulating agents for higher hemoglobin targets.
In a phase 2 trial, roxadustat maintained hemoglobin levels over 19 weeks as well as epoetin alfa.
In a case-control study, the treatment did not adversely affect mortality or recovery from AKI.
Study shows benefit of initiating epoetin beta therapy at hemoglobin levels not less than 10 g/dL in non-dialysis CKD patients.
Treatment corrects anemia and improves quality of life, according to a systemic review.
Six-months of supplementation has no impact on epoetin utilization in HD patients with low 25(OH)D.